GENE ONLINE|News &
Opinion
Blog

2022-01-06| Funding

Korro Bio Raises $116 Million for RNA Editing Program

by Joy Lin
Share To

Korro Bio, a Massachusetts-based biotech, has landed $116 million in a Series B financing round to fund its RNA editing program, which will first target alpha-1 antitrypsin deficiency (AATD), an inherited disorder that affects the lungs and liver. 

Eventide Asset Management led the Series B round, which saw participation from new investors Fidelity Management & Research Company LLC, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital and an additional healthcare specialist fund. All existing investors took part, including Atlas Venture, NEA, Wu Capital, Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Cormorant Asset Management, MP Healthcare Venture Management and Alexandria Venture Investments.

Founded by Atlas Venture in 2019, Korro’s second funding round surpassed the $91.5 million it raised in Series A in Sep 2020. 

Related article: An Interview with the Co-founder of Korro Bio

 

RNA Editing to Treat AATD

 

Alpha-1 trypsin is a protein that protects the lungs from the body’s own enzymes. AATD happens when a person inherits a faulty version of the gene which regulates alpha-1 trypsin (AAT) production from one or both of their parents. A faulty copy of the gene produces a misfolded AAT protein, which sticks together and stops the protein from leaving the liver where it is produced. AAT accumulates in the liver instead, and causes toxicity.  The imbalance in AAT levels ultimately lead to damage of the lungs and scarring of the liver.

Korro Bio is taking the RNA editing route to treat AATD. Its RNA editing platform OPERA uses the base editing system found in the body to repair mutations at the RNA. OPERA specifically uses oligonucleotide guides to recruit  adenosine deaminase acting on RNA (ADAR) to edit a single RNA base – from adenosine (A) to guanosine (G).

A Tricky Target

 

However, AATD is a tricky target to treat. No cure currently exists, and the condition is mainly managed by addressing symptoms of lung or liver disease, such as using bronchodilators or antibiotics for infections. AAT augmentation, or AAT replacement therapy, is also used, where functional AAT from healthy donors is infused into the patient. 

Vertex had banked on its small molecule drug VX-864 to correct the misfolding of AAT and bring up functional AAT levels in the body. While its Phase 2 study showed that the drug did work, Vertex concluded that the magnitude of its effects did not translate into meaningful clinical benefit, and shelved its candidate to pursue others. 

Meanwhile, Arrowhead Pharmaceuticals has shot ahead of the competition by using RNA interference to treat liver disease associated with AATD. The California-based pharma’s lead asset, ARO-AAT has shown promise in Phase 2 trials. ARO-AAT also caught the attention of Takeda, which struck a deal worth over $1 billion to co-develop the drug. 

Dicerna has further confirmed the RNAi approach with positive results from Phase 1 trials of Belcesiran, its candidate for AATD. The company is currently recruiting for its Phase 2 study. 

And playing from left field is Intellia, which is pursuing a gene therapy for AATD. The company is using CRISPR/Cas9 to knock out the abnormal gene and insert a healthy gene that promotes the production of functional AAT. Last October, the company revealed preclinical findings showing the potential of gene therapy in the disease on non-human primates.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Takeda Collaborates with Immusoft to Advance Treatments in Rare Metabolic Diseases
2022-01-14
Novartis Teams Up with Alnylam to Explore Targeted Liver Therapies
2022-01-07
R&D
Gannex Pharma Announces New Dual Targeting Drug for NASH
2022-01-05
LATEST
Biotech Showcase 2022: Healing the Psyche with Psychedelia
2022-01-17
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
2022-01-17
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
2022-01-17
Shanghai’s Everest Medicines Licenses Covid-19 Oral Antivirals from Singapore’s National Drug Discovery Platform
2022-01-17
Digital Health Programme to Connect British and Taiwanese Leaders
2022-01-17
Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults
2022-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!